作者:Cynthia A. Parrish、Nicholas D. Adams、Kurt R. Auger、Joelle L. Burgess、Jeffrey D. Carson、Amita M. Chaudhari、Robert A. Copeland、Melody A. Diamond、Carla A. Donatelli、Kevin J. Duffy、Leo F. Faucette、Jeffrey T. Finer、William F. Huffman、Erin D. Hugger、Jeffrey R. Jackson、Steven D. Knight、Lusong Luo、Michael L. Moore、Ken A. Newlander、Lance H. Ridgers、Roman Sakowicz、Antony N. Shaw、Chiu-Mei M. Sung、David Sutton、Kenneth W. Wood、Shu-Yun Zhang、Michael N. Zimmerman、Dashyant Dhanak
DOI:10.1021/jm070435y
日期:2007.10.1
Kinesin spindle protein (KSP), an ATPase responsible for spindle pole separation during mitosis that is present only in proliferating cells, has become a novel and attractive anticancer target with potential for reduced side effects compared to currently available therapies. We report herein the discovery of the first known ATP-competitive inhibitors of KSP, which display a unique activity profile
Kinesin纺锤体蛋白(KSP)是负责有丝分裂期间纺锤体极点分离的ATPase,仅存在于增殖细胞中,它已成为一种新颖且有吸引力的抗癌靶标,与目前可用的疗法相比,具有降低副作用的潜力。我们在此报告了第一批已知的KSP ATP竞争性抑制剂的发现,与目前正在临床评估中的已知loop 5(L5)变构KSP抑制剂相比,KSP显示出独特的活性。该系列产品的优化导致鉴定出联苯磺酰胺20,这是一种有效的KSP抑制剂,具有野生型KSP(HCT116)或突变型KSP(HCT116 D130V)对人细胞具有体外抗增殖活性。在具有HCT116 D130V肿瘤的鼠异种移植模型中,